GlassScriptPhysician profile
Jerry M Hahn
NPI 1831181304
$5,331.36
in general payments reported to CMS, 2019-2025
30 companies · $960 in 2025
The $960 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $309 · 2021: $642 · 2022: $803 · 2023: $708 · 2024: $668 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.47 |
| Education | $277.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,543.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $815.96 | 2019-2025 | |
| Janssen Biotech, INC. | $575.37 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $346.79 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $340.45 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Scientific Affairs, LLC | $215.93 | 2019-2022 | |
| Ucb, INC. | $211.79 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $210.41 | 2022-2025 | Dupixent |
| Organogenesis INC. | $163.57 | 2023-2025 | Cygnus Dual, Via Matrix, Novachor |
| Galderma Laboratories, L.P. | $106.40 | 2021-2025 | Nemluvio |
| Alkermes, INC. | $87.04 | 2022 | |
| Amarin Pharma, INC. | $81.03 | 2020-2021 | |
| Novo Nordisk INC | $70.75 | 2019-2025 | Rybelsus, Ozempic |
| Genzyme Corporation | $69.74 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $57.02 | 2021-2025 | Airsupra, Evusheld |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $55.31 | 2022-2024 | Opzelura |
| Amgen INC. | $48.92 | 2021-2024 | Otezla |
| Supernus Pharmaceuticals, INC. | $46.74 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.91 | 2020-2024 | Spevigo, Cyltezo |
| Pfizer INC. | $43.62 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $36.71 | 2021 | |
| Celgene Corporation | $24.94 | 2019 | |
| Convatec INC. | $23.56 | 2023 | |
| Arcutis Biotherapeutics, INC. | $22.29 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.69 | 2025 | Siliq, Jublia, Cabtreo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.52 | 2023 | Xifaxan |
| Dermavant Sciences, INC. | $15.31 | 2023 | Vtama |
| Leo Pharma INC. | $12.76 | 2019 | |
| Merck Sharp & Dohme LLC | $12.26 | 2019 | |
| Mylan Specialty L.P. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.